SCHEMBL23360696

SCHEMBL23360696

CCCCCCCCC(CCCCCCCC)C(=O)OC(=O)C(O)CO

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 5/20 0.47
FFAR1 O14842 1/20 0.47
CA2 P00918 1/20 0.44
NAAA Q02083 1/20 0.43
LMNA P02545 3/20 0.42
KDM4E B2RXH2 2/20 0.42
DUSP3 P51452 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
ZDHHC7 Q9NXF8 1/20 0.42
CYP2D6 P10635 2/20 0.41
SPHK1 Q9NYA1 1/20 0.41
GMNN O75496 1/20 0.41
POLB P06746 1/20 0.41
THPO P40225 1/20 0.41
MTOR P42345 1/20 0.41
BLM P54132 1/20 0.41
TP53 P04637 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL545530 1.00 GPR84 (0.47) GPR84FFAR1CA2NAAALMNA
SCHEMBL21617315 1.00 GPR84 (0.47) GPR84FFAR1CA2NAAALMNA
SCHEMBL1123651 0.89 GPR84 (0.55) GPR84FFAR1NAAALMNAKDM4E
SCHEMBL1123301 0.89 GPR84 (0.55) GPR84FFAR1NAAALMNAKDM4E
SCHEMBL127955 0.89 GPR84 (0.55) GPR84FFAR1NAAALMNAKDM4E
SCHEMBL3075648 0.87 CA2 (0.55) GPR84FFAR1CA2NAAAZDHHC7
SCHEMBL21409705 0.87 CA2 (0.55) GPR84FFAR1CA2NAAAZDHHC7
SCHEMBL1275694 0.86 CA2 (0.58) CA2KDM4EDUSP3MEN1KMT2A
SCHEMBL11160145 0.85 CHRM1 (0.41) CA2LMNAKDM4EDUSP3CYP3A4
SCHEMBL27494921 0.85 CA2 (0.59) GPR84FFAR1CA2NAAAZDHHC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210147472-A1 SOLID FORMS AND FORMULATIONS COMPRISING A GLUCOCORTICOID RECEPTOR ANTAGONIST AND USES THEREOF ORIC PHARMACEUTICALS, INC. 2021-05-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210147472-A1 SOLID FORMS AND FORMULATIONS COMPRISING A GLUCOCORTICOID RECEPTOR ANTAGONIST AND USES THEREOF NR3C1, NR3C2, MC2R GPR84 154/4885FFAR1 116/4885CA2 3953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.